PT  - JOURNAL ARTICLE
AU  - Priya Choudhry
AU  - Olivia Gugliemini
AU  - Huimin Geng
AU  - Vishesh Sarin
AU  - Letitia Sarah
AU  - Yu-Hsiu T. Lin
AU  - Neha Paranjape
AU  - Poornima Ramkumar
AU  - Makeba Marcoulis
AU  - Donghui Wang
AU  - Paul Phojanakong
AU  - Veronica Steri
AU  - Byron Hann
AU  - Martin Kampmann
AU  - Arun P. Wiita
TI  - Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma
AID  - 10.1101/2021.08.04.455165
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.08.04.455165
4099  - http://biorxiv.org/content/early/2021/08/06/2021.08.04.455165.short
4100  - http://biorxiv.org/content/early/2021/08/06/2021.08.04.455165.full
AB  - CD38 is a surface ectoenzyme expressed at high levels on myeloma plasma cells and is the target for the monoclonal antibodies (mAbs) daratumumab and isatuximab. CD38 density on tumor cells is an important determinant of mAb efficacy, and CD38 loss after mAb treatment may play a role in resistance. Several small molecules have been found to increase tumor surface CD38, with the goal of boosting mAb efficacy in a co-treatment strategy. Here we sought to extend our currently limited insight into CD38 surface expression by using a multi-omics approach. Genome-wide CRISPR-interference screens integrated with patient-centered epigenetic analysis confirmed known regulators of CD38, such as RARA, while revealing XBP1 and SPI1 as other key transcription factors governing surface CD38 levels. CD38 knockdown followed by cell surface proteomics demonstrated no significant remodeling of the myeloma “surfaceome” after genetically-induced loss of this antigen. Integrated transcriptome and surface proteome data confirmed high specificity of all-trans retinoic acid in upregulating CD38 in contrast to broader effects of azacytidine and panobinostat. Finally, unbiased phosphoproteomics identified inhibition of MAP kinase pathway signaling in tumor cells after daratumumab treatment. Our work provides a resource to design strategies to enhance efficacy of CD38-targeting immunotherapies in myeloma.Competing Interest StatementP.C. is currently an employee and shareholder of Genentech/Roche, though during the time of completing this project she was fully employed by the University of California, San Francisco. P.R. is currently an employee and shareholder of Senti Biosciences, though during the time of completing this project she was fully employed by the University of California, San Francisco. A.P.W. is an equity holder and scientific advisory board member of Indapta Therapeutics, LLC and Protocol Intelligence, LLC. M.K. has filed a patent application related to CRISPRi screening (PCT/US15/40449); and serves on the Scientific Advisory Boards of Engine Biosciences, Cajal Neuroscience and Casma Therapeutics. The other authors declare no relevant conflicts of interest.